Trial · NCT07094165
The Effects of Dexmedetomidine and Remifentanil on Kidney Injury After Muscle Compression Injury in Rats
NCT07094165, Not applicable, Completed, Ankara City Hospital Bilkent
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. The Effects of Dexmedetomidine and Remifentanil on Kidney Injury After Muscle Compression Injury in Rats. Trials, record NCT07094165. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07094165
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- The Effects of Dexmedetomidine and Remifentanil on Kidney Injury After Muscle Compression Injury in Rats
- NCT number
- NCT07094165
- Status
- Completed
- Phases
- Not applicable
- Enrollment
- 28 participants, actual
- Lead sponsor
- Ankara City Hospital Bilkent
- Conditions
- Acute Kidney Injury, Crush Injury, Rhabdomyolysis
- Interventions
- Dexmedetomidine, Remifentanil, Laparotomy, Compression
- First posted
- 2025-07-30
- Last updated
- 2025-07-30
Source ClinicalTrials.gov
Registered outcomes5
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Serum Creatinine Level | Baseline (0 hour), 2 hours, and 6 hours after intervention | Change in serum creatinine levels measured at 0, 2, and 6 hours after experimental crush injury in Wistar Albino rats receiving either dexmedetomidine or remifentanil. This outcome is used to assess renal function and the nephroprotective effect of the interventions. |
| Secondary | Neutrophil Gelatinase-Associated Lipocalin (NGAL) Level | 0, 2, and 6 hours after intervention | NGAL levels measured in serum at three time points to assess early renal tubular injury following experimental crush injury and treatment with dexmedetomidine or remifentanil. NGAL is an early biomarker for acute kidney injury (AKI) and reflects renal stress. |
| Secondary | Histopathological Tubular Injury Score | At 6 hours after intervention (after sacrifice) | Histopathological evaluation of renal tissue samples using scoring for tubular necrosis, brush border loss, dilatation, congestion, and apoptotic cell count. Quantitative damage scoring was performed blindly by two pathologists to compare the nephroprotective effects of dexmedetomidine and remifentanil. |
| Secondary | Kidney Injury Molecule-1 (KIM-1) Level | 0, 2, and 6 hours after intervention | Serum levels of KIM-1 measured by ELISA to evaluate renal tubular epithelial injury and compare the protective effects of the two anesthetic agents. |
| Secondary | TIMP-2) × (IGFBP7) Product Level | The combined serum levels of TIMP-2 and IGFBP7, representing G1 cell cycle arrest, were measured to detect early renal stress and predict AKI development in the experimental model. | 0, 2, and 6 hours after intervention |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers11
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07094165
GET https://conductscience.org/api/trials/v1/NCT07094165/registered